Palvella Therapeutics (PVLA) Other Non Operating Income (2014 - 2026)
Palvella Therapeutics (PVLA) reported Other Non Operating Income of -$32000.0 for Q1 2026, up 57.33% year-over-year from -$20339.0 in Q1 2025, and down 105.7% on a QoQ basis from $561000.0 in Q2 2025.
Palvella Therapeutics (PVLA) has 13 years of Other Non Operating Income data on file, last reported at -$32000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 57.33% year-over-year to -$32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $529000.0 (up 67.41% YoY) and the FY2024 annual result came in at $1.1 million, changed N/A from the prior year.
- Other Non Operating Income declined to -$32000.0 in Q1 2026 per PVLA's latest filing, from $561000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.2 million in Q4 2024 and bottomed at -$568000.0 in Q3 2024.
- The 5-year median for Other Non Operating Income is -$44500.0 (2023), against an average of $172500.0.
- Peak annual rise in Other Non Operating Income reached 527.08% in 2024, while the deepest fall reached 212.25% in 2024.
- Tracing PVLA's Other Non Operating Income over 5 years: stood at $723000.0 in 2022, then plunged by 139.83% to -$288000.0 in 2023, then surged by 527.08% to $1.2 million in 2024, then tumbled by 54.39% to $561000.0 in 2025, then slumped by 105.7% to -$32000.0 in 2026.
- Per Business Quant, the three latest PVLA Other Non Operating Income figures stand at -$32000.0 (Q1 2026), $561000.0 (Q2 2025), and -$75000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,000.00 |
| Jun 30, 2025 | 561,000.00 |
| Mar 31, 2025 | -75,000.00 |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | -568,000.00 |
| Jun 30, 2024 | -271,000.00 |
| Mar 31, 2024 | -58,000.00 |
| Dec 31, 2023 | -288,000.00 |
| Sep 30, 2023 | 506,000.00 |
| Jun 30, 2023 | -161,000.00 |
| Mar 31, 2023 | -57,000.00 |
| Sep 30, 2022 | 723,000.00 |
| Jun 30, 2022 | 676,000.00 |
| Mar 31, 2022 | 229,000.00 |
| Dec 31, 2021 | 378,000.00 |
| Sep 30, 2021 | 678,000.00 |
| Jun 30, 2021 | 464,000.00 |
| Mar 31, 2021 | 884,000.00 |
| Dec 31, 2020 | -1.83 Mn |
| Sep 30, 2020 | -1.34 Mn |
| Jun 30, 2020 | -424,000.00 |
| Mar 31, 2020 | -60,000.00 |
| Dec 31, 2019 | 177,000.00 |
| Sep 30, 2019 | -55,000.00 |
| Jun 30, 2019 | 23,000.00 |
| Mar 31, 2019 | -171,000.00 |
| Dec 31, 2018 | 331,000.00 |
| Sep 30, 2018 | 1.15 Mn |
| Jun 30, 2018 | 1.23 Mn |
| Mar 31, 2018 | -903,000.00 |
| Dec 31, 2017 | 995,000.00 |
| Sep 30, 2017 | -1.73 Mn |
| Jun 30, 2017 | -1.38 Mn |
| Mar 31, 2017 | 12,000.00 |
| Dec 31, 2016 | 6,425.00 |
| Sep 30, 2016 | -18,243.00 |
| Jun 30, 2016 | -87,801.00 |
| Mar 31, 2016 | 219,620.00 |
| Dec 31, 2015 | 7,580.00 |
| Sep 30, 2015 | -1,929.00 |
| Jun 30, 2015 | 4,484.00 |
| Mar 31, 2015 | 769.00 |
| Sep 30, 2014 | 148.00 |
| Jun 30, 2014 | 2,081.00 |
| Mar 31, 2014 | 583.00 |